The Panel on Antiretroviral Guidelines for Adults and Adolescents updated the following section

View as a webpage  /  Share September 1, 2022 Updates to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) updated the following section of the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Highlights from the section are summarized below: Drug–Drug Interactions Tables The Panel updated the Drug–Drug Interactions tables (Tables 24a–f) with guidance on the interaction potentials between antiretroviral drugs and antiviral drugs (brincidofovir, cidofovir, or tecovirimat) that are currently being used to treat monkeypox. For a complete list of updates, please see What's New in the Guidelines. To view or download the guidelines, please see the Adult and Adolescent ARV Guidelines section of Clinical Info's website. The guidelines tables and recommendations can also be downloaded as separate PDF files. Clinical Info welcomes your feedback on the latest revisions to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Please send your comments with the subject line "Adult and Adolescent ARV Guidelines" to HIVinfo@NIH.gov by September 22, 2022. Stay Connected with HIVinfo:       SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

 

---

You are subscribed as myhcistech.healthnews360@blogger.com.  Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit the GovDelivery Subscriber Help Center at https://insights.govdelivery.com/Communications/Subscriber_Help_Center.

This service is provided in collaboration with NIH's Office of AIDS Research and HHS Office of Infectious Disease and HIV/AIDS Policy/HIV.gov.

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: HIVinfo · 8600 Rockville Pike · Bethesda, MD 20894 · 888-346-3656